A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

Completed · Phase 1

Conditions studied: Multiple Myeloma

In brief

This is a first in human study which will assess the safety and tolerability of a monoclonal antibody against ICAM-1 in patients with Multiple Myeloma. The tumour response rate will also be measured.

Key facts

Study ID

NCT01025206

Run by

BioInvent International AB

People needed

35

Starts

2009-12-01

Expected to finish

2013-02-01

Last updated by the study team

2013-03-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced Myeloma with measurable disease after at least 2 previous regimens.
• Life expectancy > 3 months.
• Performance status ECOG < 2.

You may not qualify if…

• Prior antineoplastic therapy within 4 weeks prior to inclusion.
• No high dose steroids within 7 days prior to screening.
• Severe other conditions.

Where it is running

• University of Maryland, Greenebaum Cancer Center — Baltimore, Maryland, United States
• University of Utah Health Sciences Center, Department of Medicine, Division of Hematology, Utah Blood and Marrow Transplant and Myeloma Program — Salt Lake City, Utah, United States
• AZ Sint-Jan — Bruges, Belgium
• Ghent University Hospital — Ghent, Belgium
• Rigshospitalet — Copenhagen, Denmark
• Karolinska University Hospital — Huddinge, Sweden
• Hematology Clinic Cancer Division, Skåne University Hospital — Lund, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.